Myeloid malignancies develop through the accumulation of genetic and epigenetic
alterations that dysregulate hematopoietic stem cell (HSC) self-renewal, stimulate HSC …

Cancer is recognized as a preeminent factor of the world's mortality. Although various
modalities have been designed to cure this life-threatening ailment, a significant impediment …

Using targeted single-cell DNA sequencing approaches, two articles in Nature and Nature
Communications have now firmly established that acute myeloid leukemia is a highly …

Recent studies have shown that short non‐coding RNAs, known as microRNAs (miRNAs)
and their dysregulation, are implicated in the pathogenesis of acute myeloid leukaemia …

NRAS and KRAS activating point mutations are present in 10–30% of myeloid malignancies
and are often associated with a proliferative phenotype. RAS mutations harbor allele …

Hematological malignancies are characterized by a block in differentiation, which in many
cases is caused by recurrent mutations affecting the activity of hematopoietic transcription …

Acute myeloid leukemia (AML) is a poor prognosis hematopoietic malignance characterized
by abnormal proliferation and differentiation of hematopoietic stem cells (HSCs). Although …

Summary Acute Myeloid Leukemia (AML) is caused by multiple mutations which dysregulate
growth and differentiation of myeloid cells. Cells adopt different gene regulatory networks …

Acute myeloid leukaemia (AML) is a heterogeneous haematopoietic malignancy caused by
recurrent mutations in haematopoietic stem and progenitor cells that affect both the …

Vast disease heterogeneity in AML stems from between-and intra-patient genetic and
epigenetic variability, cell-of-origin effects and cell differentiation state variation. As such …